The calcium binding of erythrocyte membrane was determined in spontaneous hypertensiverats (SHR)and renovascular hypertensive rats (RVHR two-kidney, one-clip model) and the effect ofsodium tanshinone Ⅱ-A sulfonate(DS...The calcium binding of erythrocyte membrane was determined in spontaneous hypertensiverats (SHR)and renovascular hypertensive rats (RVHR two-kidney, one-clip model) and the effect ofsodium tanshinone Ⅱ-A sulfonate(DS-201)on the calcium binding in SHRs was investigated. Ourresults show that the basal calcium binding was reduced in SHRs (P<0.01 vs WKY),while the maximalcalcium binding was not,but both typies calcium bindings had no significant change in RVHRs.Sodiumtanshinone Ⅱ-A sulfonate (125μ mol/L)have no effect on the calcium binding of ecythrocyte membraneof SHR in vitro.These data further support the hypothesis that there is a cell membrane abnormalitypresent in SHRs which may possibly serve as a marker genetics of in hypertension.展开更多
Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized contro...Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized controlled trials（RCTs） of UAP treated by STS were searched in the China National Knowledge Infrastructure Database（CNKI）, VIP Database for Chinese Technical Periodicals（VIP）, Wanfang Database, the Chinese Biomedical Literature Database（CBM）, Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results： The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine（WM） in the treatment of UAP can obviously improve the total effective rate [risk ratio（RR）=1.31, 95% confidence interval（CI）（1.24,1.39）, P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI（1.30,1.56）, P〈0.0001], decrease the level of CRP [mean difference（MD）=–3.06, 95%CI（–3.85, –2.27）, P〈0.00001], fibrinogen [MD=–1.03, 95% CI（–1.16, –0.89）, P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI（–0.92, –0.49）, P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI（1.28, 9.94）, P〈0.05]. Conclusions： Compared with WM, the combined use of STS was more effective.展开更多
目的观察丹参酮ⅡA磺酸钠注射液对病毒性心肌炎模型小鼠冠状动脉血管内皮损伤的保护作用并探讨其机制。方法取Balb/c小鼠60只,选取其中40只,采用连续3 d腹腔接种柯萨奇病毒B3(CVB3Nancy株)的方法建立小鼠病毒性心肌炎模型,10 d后随机分...目的观察丹参酮ⅡA磺酸钠注射液对病毒性心肌炎模型小鼠冠状动脉血管内皮损伤的保护作用并探讨其机制。方法取Balb/c小鼠60只,选取其中40只,采用连续3 d腹腔接种柯萨奇病毒B3(CVB3Nancy株)的方法建立小鼠病毒性心肌炎模型,10 d后随机分为病毒性心肌炎模型组和丹参组,另20只作空白对照。其中丹参组按2.0 m L/(kg·d)尾静脉注射丹参酮ⅡA磺酸钠注射液治疗7 d,心肌炎模型组和空白对照组注射等体积0.9%氯化钠注射液。取治疗前后静脉血和小鼠心脏并分离出冠状动脉血管,采用酶联免疫吸附法检验小鼠血清肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、乳酸脱氢酶(LDH)、氧化物歧化酶(SOD)及丙二醛(MDA)。采用免疫组化染色检测冠状动脉血管内皮诱导型一氧化氮合酶(i NOS)的表达,双抗体夹心法测定冠状动脉血管内皮因子(VEGF)表达,反转录-聚合酶链反应(RT-PCR)检测冠状动脉血管VEGF m RNA。结果治疗后,丹参组血清CK、CK-MB、LDH及MDA较治疗前和心肌炎模型组明显降低、SOD明显提高(P<0.05);冠状动脉i NOS阳性表达减少,与治疗前和心肌炎模型组比较差异有统计学意义(P<0.05);VEGF及VEGF m RN高表达并高于心肌炎模型组和空白对照组,与治疗前、空白对照组和心肌炎模型组比较差异有统计学意义(P<0.05)。结论丹参酮ⅡA磺酸钠注射液可减轻CVB3 Nancy株对Balb/c小鼠冠状动脉血管内皮造成的损伤,对病毒性心肌炎模型心肌具有保护作用。展开更多
文摘The calcium binding of erythrocyte membrane was determined in spontaneous hypertensiverats (SHR)and renovascular hypertensive rats (RVHR two-kidney, one-clip model) and the effect ofsodium tanshinone Ⅱ-A sulfonate(DS-201)on the calcium binding in SHRs was investigated. Ourresults show that the basal calcium binding was reduced in SHRs (P<0.01 vs WKY),while the maximalcalcium binding was not,but both typies calcium bindings had no significant change in RVHRs.Sodiumtanshinone Ⅱ-A sulfonate (125μ mol/L)have no effect on the calcium binding of ecythrocyte membraneof SHR in vitro.These data further support the hypothesis that there is a cell membrane abnormalitypresent in SHRs which may possibly serve as a marker genetics of in hypertension.
基金Supported by the National Natural Science Foundation of China(No.81473547 and No.81673829)
文摘Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized controlled trials（RCTs） of UAP treated by STS were searched in the China National Knowledge Infrastructure Database（CNKI）, VIP Database for Chinese Technical Periodicals（VIP）, Wanfang Database, the Chinese Biomedical Literature Database（CBM）, Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results： The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine（WM） in the treatment of UAP can obviously improve the total effective rate [risk ratio（RR）=1.31, 95% confidence interval（CI）（1.24,1.39）, P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI（1.30,1.56）, P〈0.0001], decrease the level of CRP [mean difference（MD）=–3.06, 95%CI（–3.85, –2.27）, P〈0.00001], fibrinogen [MD=–1.03, 95% CI（–1.16, –0.89）, P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI（–0.92, –0.49）, P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI（1.28, 9.94）, P〈0.05]. Conclusions： Compared with WM, the combined use of STS was more effective.
文摘目的观察丹参酮ⅡA磺酸钠注射液对病毒性心肌炎模型小鼠冠状动脉血管内皮损伤的保护作用并探讨其机制。方法取Balb/c小鼠60只,选取其中40只,采用连续3 d腹腔接种柯萨奇病毒B3(CVB3Nancy株)的方法建立小鼠病毒性心肌炎模型,10 d后随机分为病毒性心肌炎模型组和丹参组,另20只作空白对照。其中丹参组按2.0 m L/(kg·d)尾静脉注射丹参酮ⅡA磺酸钠注射液治疗7 d,心肌炎模型组和空白对照组注射等体积0.9%氯化钠注射液。取治疗前后静脉血和小鼠心脏并分离出冠状动脉血管,采用酶联免疫吸附法检验小鼠血清肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、乳酸脱氢酶(LDH)、氧化物歧化酶(SOD)及丙二醛(MDA)。采用免疫组化染色检测冠状动脉血管内皮诱导型一氧化氮合酶(i NOS)的表达,双抗体夹心法测定冠状动脉血管内皮因子(VEGF)表达,反转录-聚合酶链反应(RT-PCR)检测冠状动脉血管VEGF m RNA。结果治疗后,丹参组血清CK、CK-MB、LDH及MDA较治疗前和心肌炎模型组明显降低、SOD明显提高(P<0.05);冠状动脉i NOS阳性表达减少,与治疗前和心肌炎模型组比较差异有统计学意义(P<0.05);VEGF及VEGF m RN高表达并高于心肌炎模型组和空白对照组,与治疗前、空白对照组和心肌炎模型组比较差异有统计学意义(P<0.05)。结论丹参酮ⅡA磺酸钠注射液可减轻CVB3 Nancy株对Balb/c小鼠冠状动脉血管内皮造成的损伤,对病毒性心肌炎模型心肌具有保护作用。
